Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046731 | 0.76 | MAPK1 (0.40) | MAPK1SMN1; SMN2HTR2ASIGMAR1 | |
| SCHEMBL2389059 | 0.74 | HTR2A (0.39) | HTR2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL2389487 | 0.73 | HTR2A (0.38) | HTR2ASIGMAR1 | |
| SCHEMBL2354334 | 0.71 | HTR2A (0.42) | HTR2ASIGMAR1 | |
| SCHEMBL15868570 | 0.71 | HTR2A (0.42) | MAPK1SMN1; SMN2HTR2A | |
| Methane SCHEMBL7908635 | 0.71 | MAPK1 (0.36) | MAPK1SMN1; SMN2PDK2HTR2A | |
| SCHEMBL2388621 | 0.70 | GABRA1 (0.39) | ALDH1A1SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL7599790 | 0.70 | HTR2A (0.41) | MAPK1SMN1; SMN2HTR2A | |
| SCHEMBL12745150 | 0.69 | MAPK1 (0.35) | MAPK1SMN1; SMN2HTR2ASIGMAR1 | |
| SCHEMBL24052816 | 0.68 | HTR2A (0.44) | HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | GRIN3A, OPRL1, GRIN2A | MAPK1 784/4885SMN1; SMN2 715/4885PDK2 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.